Imagine a daily pill that can help control diabetes using the body’s own insulin. John March, associate professor of biological and environmental engineering, and collaborators have achieved this feat in rats using an engineered probiotic. Their special strain of Lactobacillus produces a protein that triggers insulin release, and diabetic rats given a daily dose for three months had up to 30 percent lower blood glucose levels than untreated rats. The probiotic converted a fraction of the cells on the inside surface of the rats’ upper intestine—approximately 1 in 1,600—into insulin-pumping pancreatic mimics. The technology is being licensed to BioPancreate, a wholly-owned subsidiary of Cortendo AB, a biopharmaceutical company incorporated in Sweden and based in Radnor, Pa., which will refine the therapy for human use.
Keep Exploring
News
Autonomous drones are taking center stage in fisheries assessments across the Great Lakes. These drones deploy acoustic technology which tracks and quantifies fish populations. Acoustic surveying, which utilizes beams of sound, has traditionally...
News
Satellite-derived maps of defoliation caused by European spongy moths offer a promising solution for tracking pest outbreaks and for identifying large scale trends.
We openly share valuable knowledge.
Sign up for more insights, discoveries and solutions.
Please enter a valid email address to subscribe to the newsletter.